Prostate Cancer News on BioPortfolio

FDA approves J&J prostate cancer treatment

Reuters The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada treatment for use in prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.

Steroid 17 Alpha Hydroxylase1720 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 Pipeline Review H1 2018 Report Updated

Steroid 17 Alpha Hydroxylase1720 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 Pipeline Review H1 2018SummarySteroid 17 Alph...

Sequencing Questions Remain in Prostate Cancer Paradigm

Christopher Sweeney MBBS discusses the role of abiraterone for patients with hormonesensitive prostate cancer and what physicians should consider when choosing between abiraterone and docetaxel.

Pages